Peptide MOTS-c OXY-MOTS (10mg) OxyPharma

Catalogue entry: Peptide MOTS-c OXY-MOTS (10mg) OxyPharma. Labelled content: 10 mg. Listed pack: 1 vial. The amount identifies labelled product content, not an administration dose.

Identity and mechanism

MOTS-c is a mitochondrial-derived peptide containing 16 amino acids. Research connects it with metabolic stress responses and exercise biology. Studying an endogenous signalling peptide is different from establishing the effects of a separately manufactured preparation. Its relationship to cellular energy does not make it a substitute for NAD+ or a direct endurance agent.

What the research measured

Lee and colleagues described MOTS-c and metabolic homeostasis in Cell Metabolism in 2015. Reynolds and colleagues reported further exercise-related work in Nature Communications in 2021, combining experimental models with observations relevant to human exercise biology. A rise in an endogenous marker during exercise does not establish the benefit of administering an external compound.

Sporting claims and limitations

Sporting claims often invoke mitochondrial efficiency, endurance or improved recovery. These outcomes require controlled human intervention evidence rather than a pathway diagram or animal performance result. Long-term safety, tissue exposure and effects in different populations remain important uncertainties. SR-9009 targets another experimental system; a shared metabolic theme is not shared evidence.

Product identity and documentation

For the selected item, check whether documentation verifies the actual peptide sequence, chemical form and batch. Stability and formulation information matter when comparing laboratory material with a supplier preparation. A label quantity cannot establish physiological exposure or clinical suitability. The research context helps explain why MOTS-c is studied while keeping product identity and unproven sporting claims separate.